

Publication list (PEER REVIEWED)**Total Publications: 376 - H INDEX TOTAL: 65 (Scopus), Total Citations: 14118 (Scopus);**

1. Stocchi F, Ruggieri S, Baronti F, Bellantuono P, Brughitta G, **Antonini A**, Bravi D, Agnoli A: [On-off phenomena in Parkinson's disease: the continuous dopaminergic stimulation]. *La Clinica Terapeutica* 1987; 122:83-88
2. Ruggieri S, Stocchi F, Bellantuono P, **Antonini A**, Carta A, Agnoli A: Lisuride infusion in chronically treated fluctuating Parkinson's disease: effects of continuous dopaminergic stimulation. *New Trends in Clinical Neuropharmacology* 1987; 1:55-60
3. Stocchi F, Ruggieri S, **Antonini A**, Baronti F, Brughitta G, Bellantuono P, Bravi D, Agnoli A: Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration. *J Neural Transm* (suppl 27); 1988 27-33
4. Agnoli A, Stocchi F, Carta A, **Antonini A**, Bragoni M, Ruggieri S: Continuous dopamine stimulation in the management of complicated Parkinson's disease. *The Mount Sinai Journal of Medicine* 1988; 55:62-66
5. Ruggieri S, Carta A, Stocchi F, **Antonini A**, Bellantuono P, Monge A: Pharmacological strategies for controlling motor fluctuations in Parkinson's disease. *Functional Neurology* 1988; 3(4):471-479
6. Carta A, Stocchi F, Brughitta G, **Antonini A**, Ruggieri S, Agnoli A: An overview of new therapeutic strategies in Parkinson's disease. *Functional Neurology* 1989; 4(4) (Suppl 2):53-57
7. Stocchi F, Carta A, Berardelli A, **Antonini A**, Argenta M, Formica, Agnoli A. Effects of terguride in patients with Huntington's disease. *Clin Neuropharmacol* 1989; 12(5):435-439
8. Hajek M, **Antonini A**, Leenders KL, Wieser HG: Epilepsia partialis continua studied by PET. *Epilepsia Research* 1991; 9: 44-48
9. Hajek M, **Antonini A**, Leenders KL, Wieser HG: Mesial versus lateral temporal lobe epilepsy: metabolic changes shown by interictal 18F-FDG positron emission tomography. *Neurology* 1993; 43:79-86
10. **Antonini A**, Leenders KL, Reist H, Thomann R, Beer HF, Locher J: The effect of age on dopamine D2 receptors in normal human brain measured by positron emission tomography (PET) and [11C]raclopride. *Archives of Neurology* 1993; 50:474-480
11. **Antonini A**, Leenders KL, Meier D, Oertel WH, Boesiger P, Anliker M: T2 relaxation time in patients with Parkinson's disease. *Neurology* 1993; 43:697-700
12. Leenders KL, **Antonini A**, Thomann R, Locher J Th, Maitre L, Gerebtzoff A, Beer H-F, Ametamey S, Weinreich R, Gnirss F, Ofner S, Schilling W, Waldmeier PC: Svoxepine: striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET). *European J Clinical Pharmacology* 1993; 44:135-140
13. Weindl A, Kuwert T, Leenders KL, Poremba M, Conrad B, Gräfin von Einsiedel H, **Antonini A**, Herzog H, Scholz D, Feinendegen LE, Conrad B: Increased striatal glucose consumption in Sydenham's chorea. *Movement Disorders*. 1993; 8:437-444
14. Garrido JM, Mena MA, Correa C, Herreras O, Jorge P, Leenders KL, **Antonini A**, Günther I, Psylla M, de Yebenes JG: Side effects of the catechol-O-methyl-transferase inhibitor, Ro 40-7592, in rabbits. *Clinical Neuropharmacology* 1994; 17:270-276
15. Schwarz J, **Antonini A**, Kraft E, Tatsch K, Vogl T, Kirsch CM, Leenders KL, Oertel WH: Treatment with D-Penicillamine improves dopamine D2 receptor binding and T2-signal intensity in de novo Wilson's disease. *Neurology* 1994; 44:1079-1082
16. **Antonini A**, Schwarz J, Oertel WH, Beer HF, UD Madeja, Leenders KL: [11C]Raclopride and Positron Emission Tomography in Previously Untreated Patients with Parkinson's Disease: Influence of L-dopa and Lisuride Therapy on Striatal Dopamine D2 Receptors. *Neurology* 1994; 44:1325-1329
17. Hajek M, Wieser HG, Khan N, **Antonini A**, Schrott PR, Maguire P, Beer HF, Leenders KL: Preoperative and postoperative glucose consumption in mesial and lateral temporal lobe epilepsy. *Neurology* 1994; 44:2125-2132.
18. Khan N, **Antonini A**, Parkes D, Dahlitz MJ, Meier-Ewert K, Weindl A, Leenders KL: Striatal Dopamine D2 Receptors in Patients with Narcolepsy Measured with PET and 11C-Raclopride. *Neurology* 1994; 44:2101-2104.
19. Leenders KL, **Antonini A**, Schwarzbach R, Smith-Jones P, Reist H, Ben-Shachar D, Youdim M, Henn V: Blood-to-brain iron uptake in one Rhesus monkey using 52Fe-citrate and positron emission tomography (PET): influence of haloperidol. *Journal of Neural Transmission*. 1994 (suppl 43); 123-132
20. Schwarz J, **Antonini A**, Tatsch K, Kirsch CM, Oertel WH, Leenders KL: Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism. *Nuclear Medicine Communications* 1994; 15:806-813
21. Pezzoli G, **Antonini A**, Barbieri S, Canesi M, Perbellini L, Zecchinelli A, Mariani CB, Bonetti A, Leenders KL: n-Hexane induced parkinsonism: pathogenetic hypotheses. *Movement Disorders* 1995; 10:279-282
22. Günther I, Psylla M, Reddy G, **Antonini A**, Vontobel P, Reist H, Zollinger A, Leenders KL: PET in drug evaluation: influence of three different COMT inhibitors on peripheral metabolism of [NCA]6-[18F]fluoro-L-dopa in Rhesus monkey. *Nuclear Medicine and Biology* 1995; 22:921-927
23. **Antonini A**, Vontobel P, Psylla M, Günther I, Maguire R, Missimer J, Leenders KL: Complementary PET studies of the striatal dopaminergic system in Parkinson's Disease. *Archives of Neurology* 1995; 52:1183-1192
24. Ametamey SM, Beer HF, Günther I, **Antonini A**, Leenders KL, Waldmeier PC, Schubiger PA. Radiosynthesis of [11C]brofaromine, a potential tracer for imaging MAO-A. *Nuclear Medicine and Biology* 1996; 23:229-234
25. Boecker H, Weindl A, Leenders KL, **Antonini A**, Kuwert T, Kruggel, H. Gräfin V. Einsiedel H, Conrad B: Secondary parkinsonism due to focal substantia nigra lesions: regional cerebral glucose utilisation and dopa-decarboxylase studied using PET *Acta Neurol Scand* 1996; 93:387-392
26. Chaly T, Dhawan V, Kazumata K, **Antonini A**, Margouloff C, Dhal JR, Belakhlef A, Margouloff D, Yee A, Wang S, Tamagnan G, Neumayer JL, Eidelberg D: Radiosynthesis of [18F]N-3-Fluoropropyl-2-³-Carbomethoxy-3-³-

- (4-Iodophenyl) Nortropane and the first human study with Positron Emission Tomograph *Nuclear Medicine and Biology* 1996; 23:999-1004
27. **Antonini A**, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, Sanchez-Pernaute R, de Yebanez JG, Weindl A, Maguire R: Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene mutation carriers and patients with Huntington's disease *Brain* 1996; 119:2085-2095
 28. Lu D, Margouleff C, Rubin E, Labar D, Schaul N, Ishikawa T, Kazumata K, **Antonini A**, Dhawan V, Hyaman RA, Eidelberg D: Temporal lobe epilepsy: correlation of proton magnetic resonance spectroscopy and [18F]fluorodeoxyglucose positron emission tomography. *Magnetic Resonance in Medicine* 1997; 37:18-23
 29. **Antonini A**, Schwarz J, Oertel WH, Pogarell O, Leenders KL: Long-term Changes of Striatal Dopamine D2 Receptors in Patients with Parkinson's Disease: a Study with PET and [11C]Raclopride. *Movement Disorders* 1997; 12:33-38
 30. Magyar S, **Antonini A**, Roelcke U, Leenders KL: Cerebral glucose metabolism in patients with spasmodic torticollis. *Movement Disorders* 1997; 12:704-708
 31. Eidelberg D, Moeller JM, **Antonini A**, Kazumata K, Dhawan V, Budman C, Feigin A: The metabolic anatomy of Tourette syndrome. *Neurology* 1997; 48:927-934
 32. Eidelberg D, Moeller JM, Kazumata K, **Antonini A**, Sterio D, Dhawan V, Spetsieris P, Alterman R, Kelly P, Dogali M, Fazzini E, Beric A: Metabolic correlates of pallidal activity in Parkinson's disease. *Brain* 1997; 120:1315-1324
 33. Vollenweider FX, Leenders K, Scharfetter C, **Antonini A**, Oye I, Hell D, Angst J: Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). *European Neuropsychopharmacology* 1997; 7:9-24
 34. Psylla M, Guenther I, **Antonini A**, Vontobel P, Reist HW, Zollinger A, Leenders KL: Cerebral 6-[18F]fluoro-L-dopa uptake in Rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition. *Brain Research* 1997; 767:45-54
 35. Kazumata K, **Antonini A**, Dhawan V, Moeller JR, Alterman RL, Kelly P, Fazzini E, Sterio D, Beric A, Eidelberg D: Preoperative indicators of clinical outcome following stereotactic pallidotomy. *Neurology* 1997; 49:1083-1090
 36. Khan N, Hajek M, **Antonini A**, Maguire P, Mueller S, Wieser HG, Valavanis A, Leenders KL: Cerebral metabolic changes (18F-FDG-PET) during selective anterior temporal lobe amobarbital test. *European Neurology* 1997; 38:268-275
 37. **Antonini A**, Kazumata K, Feigin A, Mandel F, Dhawan V, Margouleff C, Eidelberg D: Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. *Movement Disorders* 1998 Mar;13(2):268
 38. de Yébenes JG, Pernaute RS, Garrido JM, Rábano A, Albusua J, Rojo A, Mena MA, Ruiz PG, Jorge P, Correa C, Leenders K, **Antonini A**, Gunther I, Psylla M, Vontobel P: Long-term intracerebral infusion of fibroblast growth factors restores motility and enhances F-DOPA uptake in parkinsonian monkeys. *Parkinsonism and Related Disorders* 11/1998; 4(3):147-58.
 39. **Antonini A**, Leenders KL, Vontobel P, Maguire RP, Missimer J, Psylla M, Guenther I: Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. *Brain* 1997; 120:2187-2195
 40. **Antonini A**, Leenders KL, Eidelberg D: [11C]Raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. *Annals of Neurology* 1998; 43:253-255
 41. **Antonini A**, Moeller J, Dhawan V, Eidelberg D: The metabolic anatomy of tremor in Parkinson's disease. *Neurology* 1998; 51(3):803-10
 42. Bisaga A, Katz JL, **Antonini A**, Gorman JM, Wright CE, Margouleff C, Eidelberg D: Cerebral glucose metabolism in women with panic disorder. *Archives of Psychiatry* 1998;155(9):1178-1183
 43. Eidelberg D, Moeller JR, **Antonini A**, Kazumata K, Nakamura T, Dhawan V, Spetsieris P, deLeon D, Bressman SB, Fahn S: Functional brain networks in DYT1 dystonia. *Ann Neurol* 1998 Sep;44(3):303-12
 44. Kazumata K, Dhawan V, Chaly T, **Antonini A**, Margouleff C, Belakhlef A, Neumeyer J, Eidelberg D: Dopamine transporter imaging with fluorine-18-FPCIT and PET. *J Nucl Med*. 1998 Sep;39(9):1521-30
 45. Trenkwalder C, Walters AS, Hening WA, Chokroverty S, **Antonini A**, Dhawan V, Eidelberg D: Positron Emission Tomographic Studies in the Restless Legs Syndrome. *Mov Disord*. 1999 Jan;14(1):141-5
 46. Kuenig G, Leenders KL, **Antonini A**, Vontobel P, Weindl A, Meinck HM: D2 receptor binding in dopa-responsive dystonia. *Annals of Neurology* 1998 Nov 44(5):758-62
 47. Moeller JR, Nakamura T, Mentis MJ, Dhawan V, Spetsieris P, **Antonini A**, Missimer J, Leenders KL, Eidelberg D: Reproducibility of regional metabolic covariance patterns: comparison of four populations. *J Nucl Med* 1999 Aug;40(8):1264-9
 48. Canesi M, **Antonini A**, Mariani C, Tesesi S, Zecchinelli A, Barichella M, Pezzoli G: An overnight switch to ropinirole therapy in patients with Parkinson's disease. *Journal of Neural Transmission* 1999;106:925-9
 49. Linzasoro G, Obeso JA, Gomez JC, Martinez M, **Antonini A**, Leenders KL: Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET *Clin Neuropharmacol* 1999 ; 22(5):277-80
 50. Canesi M, **Antonini A**, Colzi A, Bravi D, Pezzoli G: Olanzapine reduces levodopa-related dyskinesias in patients with Parkinson's disease *European Neuropsychopharmacology* 1999; 9:289-289.
 51. Kunig G, Leenders KL, Sanchez-Pernaute R, **Antonini A**, Vontobel P, Verhagen A, Gunther I: Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography. *Ann Neurol* 2000 May;47: 644-8
 52. Bruehlmeier M, Leenders KL, Vontobel P, Calonder C, **Antonini A**, Weindl A: Increased cerebral iron uptake in Wilson's disease: a 52Fe-citrate PET study. *J Nucl Med* 2000; 41:781-7
 53. Ghilardi M, Ghez C, Dhawan V, Moeller J, Mentis M, Nakamura T, **Antonini A**, Eidelberg D: Patterns of regional brain activation associated with different forms of motor learning. *Brain Res* 2000 Jul 14;871(1):127-145

54. Tesei S, **Antonini A**, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G: Tolerability of paroxetine in Parkinson's disease: a prospective study. *Movement Disorders* 2000;15:986-9
55. Pezzoli G, Canesi M, **Antonini A**, Righini A, Perbellini L, Barichella M, Mariani CB, Tenconi F, Tesei S, Zecchinelli A, Leenders KL: Hydrocarbon exposure and Parkinson's disease. *Neurology* 2000;55:667-673
56. Hutchinson M, Nakamura T, Moeller JR, **Antonini A**, Belakhlef A, Dhawan V, Eidelberg D: The metabolic topography of essential blepharospasm: a focal dystonia with general implications. *Neurology* 2000; 55:667-673
57. Fukuda M, Mentis M, Ghilardi MF, Dhawan V, **Antonini A**, Hammerstad J, Lozano AM, Lang A, Lyons K, Koller W, Ghez C, Eidelberg D: Functional correlates of pallidal stimulation for Parkinson's disease. *Ann Neurol.* 2001;49(2):155-64
58. Fukuda M, Mentis MJ, Ma Y, Dhawan V, **Antonini A**, Lang AE, Lozano AM, Hammerstad J, Lyons K, Koller WC, Moeller JR, Eidelberg D: Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. *Brain.* 2001 Aug;124(Pt 8):1601-9
59. **Antonini A**, De Notaris R, Benti R, De Gaspari D, Pezzoli G: Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. *Neurol Sci.* 2001;22(1):45-6
60. **Antonini A**, Moresco RM, Gobbo C, De Notaris R, Panzacchi A, Barone P, Calzetti S, Negrotti A, Pezzoli G, Fazio F: The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [¹¹C]FE-CIT. *Neurol Sci.* 2001;22(1):47-8
61. Feigin A, Leenders KL, Moeller JR, Missimer J, Kuenig G, Spetsieris P, **Antonini A**, Eidelberg D: Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. *J Nucl Med* 2001 Nov;42(11):1591-5
62. Righini A, **Antonini A**, Ferrarini M, de Notaris R, Canesi M, Triulzi F, Pezzoli G: Thin section MR study of the basal ganglia in the differential diagnosis between striatonigral degeneration and Parkinson disease. *J Comput Assist Tomogr* 2002 Mar-Apr;26(2):266-71
63. Rovetta A, **Antonini A**, Pignatelli F, Ragone VA: First clinical trials for neuromotor analysis. *Stud Health Technol Inform.* 2002;85:431-3
64. Lucignani G1, Gobbo C, Moresco RM, **Antonini A**, Panzacchi A, Bonaldi L, Carpinelli A, Caraceni T, Fazio F. The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using 11C-2-beta-carbomethoxy-3-beta-(4-fluorophenyl)-tropane in patients with movement disorders. *Nuclear Medicine Communications.* 2002, 23(11):1047-1055
65. D'Ausilio A, Marconi S, **Antonini A**, Tamma F, Valzania F, Berto P: [Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase] *Recenti Prog Med.* 2003 Nov;94(11):484-93
66. Di Rosa AE, Epifanio A, **Antonini A**, Stocchi F, Martino G, Di Blasi L, Tetto A, Basile G, Imbesi D, La Spina P, Di Raimondo G, Morgante L: Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. *Neurol Sci.* 2003 Oct;24(3):151-2
67. **Antonini A**, Marotta G, Benti R, Landi A, De Notaris R, Mariani C, Gerundini P, Pezzoli G, Gaini SM: Brain flow changes before and after deep brain stimulation of the subthalamic nucleus in Parkinson's disease *J Neurosurg Sci.* 2003 Mar;47(1):26-32
68. Hernandez C1, Casas A, Escarrabill J, Alonso J, Puig-Junoy J, Farrero E, Vilagut G, Collvinent B, Rodriguez-Roisin R, Roca J; Alonso, A, Montero, J.A, Pastor, J, **Antonini A.**, Castiglioni, C. Battaglia, E, Moggio, F, Mercinelli, M, Van de Werf, F, Sylvester P, Pougetoux, N. Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients. *Eur Respir J.* 2003 Jan;21(1):58-67
69. Landi A, Grimaldi M, **Antonini A**, Parolin M, Zincone A Marina: MRI indirect stereotactic targeting for deep brain stimulation in Parkinson's disease. *Neurol Sci.* 2002 Sep;23 :59-60
70. Feigin A, **Antonini A**, Fukuda M, De Notaris R, Benti R, Pezzoli G, Mentis MJ, Moeller JR, Eidelberg D: Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism *Mov Disord.* 2002 Nov;17(6):1265-70
71. Bonifati V, Dekker MC, Vanacore N, Fabbrini G, Squitieri F, Marconi R, **Antonini A**, Brustenghi P, Dalla Libera A, De Mari M, Stocchi F et al: Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7. *Neurol Sci.* 2002 Sep;23 :S59-60
72. Landi A, Parolin M, Piolti R, **Antonini A**, Grimaldi M, Crespi M, Iurlaro S, Aliprandi A, Pezzoli G, Ferrarese C, Gaini SM: Deep brain stimulation for the treatment of Parkinson's disease: the experience of the Neurosurgical Department in Monza. *Neurol Sci.* 2003 May;24 Suppl 1:S43-4
73. Landi A, Grimaldi M, **Antonini A**, Parolin M, Zincone A Marina: MRI indirect stereotactic targeting for deep brain stimulation in Parkinson's disease. *J Neurosurg Sci.* 2003 Mar;47(1):26-32
74. **Antonini A**, Landi A, Benti R, Mariani C, De Notaris R, Marotta G, Pezzoli G, Gaini SM, Gerundini P: Functional neuroimaging (PET and SPECT) in the selection and assessment of patients with Parkinson's disease undergoing deep brain stimulation. *J Neurosurg Sci.* 2003 Mar;47(1):40-6
75. **Antonini A**, Benti R, De Notaris R, Tesei S, Zecchinelli A, Sacilotto G, Meucci N, Canesi M, Mariani C, Pezzoli G, Gerundini P: 123I-IOflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. *Neurol Sci.* 2003 Oct;24(3):149-50
76. **Antonini A**, Marotta G, Benti R, Landi A, De Notaris R, Mariani C, Gerundini P, Pezzoli G, Gaini SM: Brain flow changes before and after deep brain stimulation of the subthalamic nucleus in Parkinson's disease. *Neurol Sci.* 2003 Oct;24(3):151-2
77. Landi A, **Antonini A**, Parolin M, Grimaldi M, Bassi F, Iurlaro S, Gaini SM: [Chronic subthalamus stimulation for the treatment of Parkinson's disease. Analysis of results by classes of symptoms and adverse effects] *J Neurosurg Sci.* 2003 Mar;47(1 Suppl 1):24-7 [Article in Italian]
78. **Antonini A**, DeNotaris R: PET and SPECT functional imaging in Parkinson's disease. *Sleep Med.* 2004 Mar;5(2):201-6

79. **Antonini A**, Landi A, Mariani C, DeNotaris R, Pezzoli G: Deep brain stimulation and its effect on sleep in Parkinson's disease *Sleep Med.* 2004 Mar;5(2):211-4
80. Linazasoro G, **Antonini A**, Maguire RP, Leenders KL: Pharmacological and PET studies in patient's with Parkinson's disease and a short duration-motor response: implications in the pathophysiology of motor complications. *J Neural Transm.* 2004 Apr;111(4):497-509.
81. Righini A, **Antonini A**, De Notaris R, Bianchini E, Meucci N, Sacilotto G, Canesi M, De Gaspari D, Triulzi F, Pezzoli G: MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease. *Am J Neuroradiol.* 2004 ;25(6):927-32
82. Mucchiut, M, Belgrado E, Cutuli D, **Antonini A**, Bergonzi P, Pramipexole-treated Parkinson's disease during pregnancy. *Movement Disorders* 2004 Sep;19(9):1114-5
83. Morgante L, Basile G, Epifanio A, Spina E, **Antonini A**, Stocchi F, Di Rosa E, Martino G, Marconi R, La Spina P, Nicta-Mauro V, Di Rosa AE: Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. *Arch Gerontol Geriatr Suppl.* 2004;(9):291-6
84. Bertoli-Avella AM, Giroud-Benitez JL, Akyol A, Barbosa E, Schaap O, van der Linde HC, Martignoni E, Lopiano L, Lamberti P, Fincati E, **Antonini A**, Stocchi F, Montagna P, Squitieri F, Marini P, Abbruzzese G, Fabbrini G, Marconi R, Dalla Libera A, Trianni G, Guidi M, De Gaetano A, Boff Maegawa G, De Leo A, Gallai V, de Rosa G, Vanacore N, Meco G, van Duijn CM, Oostra BA, Heutink P, Bonifati V; Italian Parkinson Genetics Network. Novel parkin mutations detected in patients with early-onset Parkinson's disease. *Mov Disord.* 2005 Apr;20(4):424-31
85. Cossu G, Cella C, Melis M, **Antonini A**, Floris GL, Ruffini L, Spissu A: [123I]FP-CIT SPECT findings in two patients with Hallervorden-Spatz disease with homozygous mutation in PANK2 gene. *Neurology.* 2005 Jan 11;64(1):167-8
86. Bonifati V, Rohe CF, Breedveld GJ, Fabrizio E, De Mari M, Tassorelli C, Tavella A, Marconi R, Nicholl DJ, Chien HF, Fincati E, Abbruzzese G, Marini P, De Gaetano A, Horstink MW, Maat-Kievit JA, Sampaio C, **Antonini A**, Stocchi F, Montagna P, Toni V, Guidi M, Dalla Libera A, Tinazzi M, De Pandis F, Fabbrini G, Goldwurm S, de Klein A, Barbosa E, Lopiano L, Martignoni E, Lamberti P, Vanacore N, Meco G, Oostra BA; Italian Parkinson Genetics Network. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. *Neurology.* 2005 Jul 12;65(1):87-95
87. Gambarin M, **Antonini A**, Moretto G, Bovi P, Romito S, Fiaschi A, Tinazzi M: Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: Case report. *Mov Disord.* 2005 21(2):270-3
88. Rango M, Canesi M, Ghione I, Farabola M, Righini A, Bresolin N, **Antonini A**, Pezzoli G: Parkinson's disease, chronic hydrocarbon exposure and striatal neuronal damage: A 1-H MRS study. *Neurotoxicology.* 2005 Mar;27(2):164-8
89. **Antonini A**, Goldwurm S, Benti R, Prokisch H, Ebhardt M, Cilia R, Zini M, Righini A, Cossu G, Pezzoli G: Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegeneration. *Mov Disord.* 2006 ;21(3):417-8
90. Goldwurm S, Di Fonzo A, Simons EJ, Rohe CF, Zini M, Canesi M, Tesei S, Zecchinelli A, **Antonini A**, Mariani C, Meucci N, Sacilotto G, Sironi F, Salani G, Ferreira J, Chien HF, Fabrizio E, Vanacore N, Dalla Libera A, Stocchi F, Diroma C, Lamberti P, Sampaio C, Meco G, Barbosa E, Bertoli-Avella AM, Breedveld GJ, Oostra BA, Pezzoli G, Bonifati V. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. *J Med Genet.* 2005 Nov;42(11):e65.
91. Cilia R, Marotta G, Benti R, Pezzoli G, **Antonini A**: Brain SPECT imaging in multiple system atrophy. *J Neural Transm.* 2005 Dec;112(12):1635-45
92. Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohe CF, Riboldazzi G, **Antonini A**, Albani G, Mauro A, Marconi R, Abbruzzese G, Lopiano L, Fincati E, Guidi M, Marini P, Stocchi F, Onofrj M, Toni V, Tinazzi M, Fabbrini G, Lamberti P, Vanacore N, Meco G, Leitner P, Uitti RJ, Wszolek ZK, Gasser T, Simons EJ, Breedveld GJ, Goldwurm S, Pezzoli G, Sampaio C, Barbosa E, Martignoni E, Oostra BA, Bonifati V: Comprehensive analysis of the LRRK2 gene in six ty families with Parkinson's disease. *Eur J Hum Genet.* 2006 Mar;14(3):322-31
93. Ceravolo R, **Antonini A**, Volterrani D, Rossi C, Goldwurm S, Di Maria E, Kiferle L, Bonuccelli U, Murri L: Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers. *Neurology.* 2005 Dec 27;65(12):1971-3
94. De Gaspari D, Siri C, Landi A, Cilia R, Bonetti A, Natuzzi F, Morgante L, Mariani CB, Sganzerla E, Pezzoli G, **Antonini A**: Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. *J Neurol Neurosurg Psychiatry.* 2006 Apr;77(4):450-3.
95. De Gaspari D, Siri C, Di Gioia M, **Antonini A**, Isella V, Pizzolato A, Landi A, Vergani F, Gaini SM, Appollonio IM, Pezzoli G: Clinical correlates and cognitive underpinnings of verbal fluency impairment after chronic subthalamic stimulation in Parkinson's disease. *Parkinsonism Relat Disord.* 2006 Jun;12(5):289-95
96. Barone P, Scarzella L, Marconi R, **Antonini A**, Morgante L, Bracco F, Zappia M, Musch B: Depression/Parkinson Italian Study Group. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. *J Neurol.* 2006 May;253(5):601-7
97. **Antonini A**, Tesei S, Zecchinelli A, Barone P, De Gaspari D, Canesi M, Sacilotto G, Meucci N, Mariani C, Pezzoli G: Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. *Mov Disord.* 2006 Aug;21(8):1119-22
98. **Antonini A** The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies. *Neuropsychiatr Dis Treat.* 2007 Jun;3(3):287-92

99. Isaias IU, Benti R, Goldwurm S, Zini M, Cilia R, Gerundini P, Di Fonzo A, Bonifati V, Pezzoli G, **Antonini A**: Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation. *Mov Disord*. 2006 Aug;21(8):1144-7
100. Casas A, Troosters T, Garcia-Aymerich J, Roca J, Hernández C, Alonso A, del Pozo F, de Toledo P, Antó JM, Rodríguez-Roisín R, Decramer M; Montero, J.A., Vallespin, B, **Antonini, A**, Castiglioni, C, Battaglia E, Moggio F, Mercinelli M, Droogne W, Van de Werf F, Sylvester P, Pougetoux, N. Integrated care prevents hospitalisations for exacerbations in COPD patients. *Eur Respir J*. 2006 Jul;28(1):123-30
101. Goldwurm S, Zini M, Di Fonzo A, De Gaspari D, Siri C, Simons EJ, van Doeselaar M, Tesei S, **Antonini A**, Canesi M, Zecchinelli A, Mariani C, Meucci N, Sacilotto G, Cilia R, Isaias IU, Bonetti A, Sironi F, Ricca S, Oostra BA, Bonifati V, Pezzoli G: LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. *Parkinsonism Relat Disord*. 2006 Oct;12(7):410-9.
102. Ottaviani S, Tinazzi M, Pasquin I, Nothdurfter W, Tomelleri G, Fincati E, Nordera G, Moretto G, Fiaschi A, Smiana N, Giorgetti P, **Antonini A**: Comparative analysis of visual and semi-quantitative assessment of striatal [(123)I]FP-CIT-SPET binding in Parkinson's disease. *Neurol Sci*. 2006 Dec;27(6):397-401
103. Vergani F, Landi A, **Antonini A**, Sganzerla EP: Bilateral subthalamic deep brain stimulation in a patient with Parkinson's disease who had previously undergone thalamotomy and autologous adrenal grafting in the caudate nucleus: case report. *Neurosurgery* 2006 Nov;59(5):E1140
104. Giordana MT, D'Agostino C, Albani G, Mauro A, Di Fonzo A, **Antonini A**, Bonifati V: Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation. *Mov Disord*. 2007 22:275-8
105. Cilia R, Landi A, Vergani F, Sganzerla E, Pezzoli G, **Antonini A**: Extradural motor cortex stimulation in Parkinson's disease. *Mov Disord*. 2007; 22:111-4
106. Marongiu R, Brancati F, **Antonini A**, Ialongo T, Ceccarini C, Scariolla O, Capalbo A, Benti R, Pezzoli G, Dallapiccola B, Goldwurm S, Valente EM: Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum. *Hum Mutat*. 2007 Jan;28(1):98
107. Zanettini R, **Antonini A**, Gatto G, Gentile R, Tesei S, Pezzoli G: Valvular heart disease and the use of dopamine agonists for Parkinson's disease. *N Engl J Med*. 2007 Jan 4;356(1):39-46
108. Grunewald A, Breedveld GJ, Lohmann-Hedrich K, Rohe CF, König IR, Hagenah J, Vanacore N, Meco G, **Antonini A**, Goldwurm S, Lesage S, Durr A, Binkofski F, Siebner H, Munchau A, Brice A, Oostra BA, Klein C, Bonifati V: Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis. *Neurogenetics* 2007 Apr;8(2):103-9
109. Vergani F, Landi A, **Antonini A**, Parolin M, Cilia R, Grimaldi M, Ferrarese C, Gaini SM, Sganzerla EP: Anatomical identification of active contacts in subthalamic deep brain stimulation. *Surg Neurol*. 2007 Feb;67(2):140-6
110. Cilia R, Siri C, Marotta G, Gaspari DD, Landi A, Mariani CB, Benti R, Isaias IU, Vergani F, Pezzoli G, **Antonini A**: Brain networks underlining verbal fluency decline during STN-DBS in Parkinson's disease: An ECD-SPECT study. *Parkinsonism Relat Disord*. 2007 Jul;13(5):290-4
111. Morgante L, Morgante F, Moro E, Epifanio A, Girlanda P, Ragonese P, **Antonini A**, Barone P, Bonuccelli U, Contarino MF, Capus L, Ceravolo MG, Marconi R, Ceravolo R, D'Amelio M, Savettieri G: How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. *Parkinsonism Relat Disord*. 2007; 13:528-31
112. Scherfler C, Schwarz J, **Antonini A**, Grosset D, Valldeoriola F, Marek K, Oertel W, Tolosa E, Lees AJ, Poewe W. Role of DAT-SPECT in the diagnostic work up of Parkinsonism. *Mov Disord*. 2007; 22:1229-38
113. **Antonini A**, Ioannis U, Isaias, Margherita Canesi, Maurizio Zibetti, Francesca Mancini, Luigi Manfredi, Marco Dal Fante, Leonardo Lopiano, Gianni Pezzoli: Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. *Mov Disord* 2007 15;22(8):1145-9
114. Thomas A, Bonanni L, **Antonini A**, Barone P, Onofrij M. Dopa-responsive pseudo-orthostatic tremor in parkinsonism. *Mov Disord*. 2007; 22:1652-6
115. **Antonini A**: Daytime somnolence and night sleep disturbances in Parkinson's disease: background and future treatment prospective. *Neurol Sci*. 2007 Jan;28 Suppl 1:S6-8
116. Canesi M, Benti R, Marotta G, Cilia R, Isaias IU, Gerundini P, Pezzoli G, **Antonini A**: Striatal dopamine transporter binding in patients with Parkinson's disease and severe occupational hydrocarbon exposure. *Eur J Neurol*. 2007 Mar;14(3):297-9
117. Cilia R, Righini A, Marotta G, Benti R, Marconi R, Isaias IU, Pezzoli G, **Antonini A**: Clinical and imaging characterization of a patient with idiopathic progressive ataxia and palatal tremor. *Eur J Neurol*. 2007 Aug;14(8):944-6
118. **Antonini A**: New strategies in motor parkinsonism. *Parkinsonism and Related Disorders* 01/2007; 13 Suppl 3:S446-9.
119. **Antonini A**: Continuous dopaminergic stimulation-From theory to clinical practice. *Parkinsonism Relat Disord*. 2007 Sep;13 Suppl:S24-8
120. **Antonini A**, Poewe W: Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. *Lancet Neurol*. 2007 Sep;6(9):826-9
121. Isaias IU, Benti R, Cilia R, Canesi M, Marotta G, Gerundini P, Pezzoli G, **Antonini A**: [123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. *Neuroreport*. 2007 Sep 17;18(14):1499-502
122. **Antonini A**: The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies. *Neuropsychiatr Dis Treat*. 2007 Jun;3(3):287-92
123. Isaias IU, Siri C, Cilia R, De Gaspari D, Pezzoli G, **Antonini A**: The relationship between impulsivity and impulse control disorders in Parkinson's disease. *Mov Disord*. 2008; 23:411-5

124. Cilia R, Marotta G, Landi A, Isaias IU, Vergani F, Benti R, Sganzerla E, Gerundini P, Pezzoli G, **Antonini A**: Cerebral activity modulation by extradural motor cortex stimulation in Parkinson's disease: a perfusion SPECT study. *Eur J Neurol*. 2008 Jan;15(1):22-8
125. Tinazzi M, Ottaviani S, Isaias IU, Pasquin I, Steinmayr M, Vampini C, Pilleri M, Moretto G, Fiaschi A, Smania N, Giorgetti P, **Antonini A**: [(123I)]FP-CIT SPET imaging in drug-induced *Parkinsonism*. *Mov Disord*. 2008
126. Ceravolo R, **Antonini A**, Volterrani D, Rossi C, Kiferle L, Frosini D, Lucetti C, Isaias IU, Benti R, Murri L, Bonuccelli U: Predictive value of nigrostriatal dysfunction in isolated tremor: A clinical and SPECT study. *Mov Disord*. 2008 23:2049-54
127. **Antonini A**, Abbruzzese G, Barone P, Bonuccelli U, Lopiano L, Onofri M, Zappia M, Quattrone A: COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features. *Neuropsychiatr Dis Treat*. 2008 Feb;4(1):1-9.
128. Prigione A, Isaias IU, Galbusera A, Brighina L, Begni B, Andreoni S, Pezzoli G, **Antonini A**, Ferrarese C: Increased oxidative stress in lymphocytes from untreated Parkinson's disease patients. *Parkinsonism Relat Disord*. 2008; 15:327-8
129. Sironi F, Primignani P, Zini M, Tunesi S, Ruffmann C, Ricca S, Brambilla T, **Antonini A**, et al. Parkin analysis in early onset Parkinson's disease. *Parkinsonism Relat Disord*. 2008;14(4):326-33. Epub 2007 Nov 19.
130. **Antonini A**: Unraveling depression in Parkinson's disease. *Eur J Neurol*. 2008 Sep;15(9):885-6
131. Defazio G, Berardelli A, Fabbrini G, Martino D, Fincati E, Fiaschi A, Moretto G, Abbruzzese G, Marchese R, Bonuccelli U, Del Dotto P, Barone P, De Vivo E, Albanese A, **Antonini A**, et al: Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. *Arch Neurol*. 2008 Sep;65(9):1191-4.
132. **Antonini A**, Berto P, Lopatriello , Tamma F, Annemans L, Chambers M: Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. *Movement Disorders* 2008; 23(15):2202-9
133. Caretti V, Stoffers D, Winogrodzka A, Isaias IU, Costantino G, Pezzoli G, Ferrarese C, **Antonini A**, Wolters E, Booij J: Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [(123I)]beta-CIT SPECT study. *Journal of Neural Transmission* 06/2008; 115(5):721-9
134. **Antonini A**, Carlo Colosimo C, Roberto Marconi R, Letterio Morgante L, Barone P The PRIAMO study: background, methods and recruitment. *Neurological Sciences* 05/2008; 29(2):61-5
135. Panzacchi A, Moresco RM, Garibotto V, **Antonini A**, Gobbo C, Isaias IU, Goldwurm S, Bonaldi L, Carpinelli A, Pezzoli G, Fazio F, Perani D: A voxel-based PET study of dopamine transporters in Parkinson's disease: relevance of age at onset. *Neurobiol Dis*. 2008 Jul;31(1):102-9
136. **Antonini A**, Mancini F, Canesi M, Zangaglia R, Isaias IU, Manfredi L, Pacchetti C, Zibetti M, Natuzzi F, Lopiano L, Nappi G, Pezzoli G. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. *Neurodegener Dis*. 2008;5(3-4):244-6
137. **Antonini A**, Isaias IU: Single photon-emission computed tomography imaging in early Parkinson's disease. *Expert Rev Neurother*. 2008 ;8(12):1853-64.
138. **Antonini A**, Mirò L, Castiglioni C, Pezzoli G. The rationale for improved integration between home care and neurology hospital services in patients with advanced Parkinson's disease *Neurol Sci*. 2008 Dec;29 Suppl 5:S392-6
139. Cilia R, Siri C, Marotta G, Isaias IU, De Gaspari D, Canesi M, Pezzoli G, **Antonini A**: Functional abnormalities underlying pathological gambling in Parkinson disease. *Arch Neurol*. 2008 Dec;65(12):1604-11
140. Odin P, Wolters E, **Antonini A**: Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. *Neurol Sci*. 2008 Dec;29 Suppl 5:S387-8
141. Canesi M, Zecchinelli AL, Pezzoli G, **Antonini A**: Clinical experience of tolcapone in advanced Parkinson's disease. *Neurol Sci*. 2008 Dec;29 Suppl 5:S380-2
142. **Antonini A**, Barone P: Dopamine agonist-based strategies in the treatment of Parkinson's disease. *Neurol Sci*. 2008 Dec;29 Suppl 5:S371-4.
143. Barone P, **Antonini A**, Colosimo C, et al: PRIAMO study group. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. *Mov Disord*. 2009 Aug 15;24(11):1641-9
144. **Antonini A**, Tolosa E: Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. *Expert Rev Neurother*. 2009 Jun;9(6):859-67
145. **Antonini A**, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. *Drug Saf*. 2009;32(6):475-88
146. Honig H, **Antonini A**, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR: Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. *Mov Disord*. 2009 Jul 30;24(10):1468-74
147. Santangelo G, Morgante L, Savica R, Marconi R, Grasso L, **Antonini A**, De Gaspari D, Ottaviani D, Tiple D, Simoni L, Barone P: PRIAMO Study Group Anhedonia and cognitive impairment in Parkinson's disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. *Parkinsonism Relat Disord*. 2009 Sep;15(8):576-81
148. **A. Antonini**, R. Cilia: Spect imaging biomarkers. *Journal of The Neurological Sciences* 2009; 283(1):268-268
149. Zoccollella S, dell'Aquila C, Abbruzzese G, **Antonini A**, Bonuccelli U, Canesi M, Cristina S, Marchese R, Pacchetti C, Zangaglia R, Logroscino G, Defazio G, Lamberti P, Livrea P: Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. *Mov Disord*. 2009 May 15;24(7):1028-33
150. Tinazzi M, **Antonini A**, Bovi T, Pasquin I, Steinmayr M, Moretto G, Fiaschi A, Ottaviani S. Clinical and [(123I)]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. *J Neurol*. 2009 Jun;256(6):910-5.
151. **Antonini A**, Isaias IU: Imaging evidence supports a link between essential tremor and Parkinson's disease. *Nucl Med Commun*. 2009 Feb;30(2):93-4

152. Grosset D, **Antonini A**, Canesi M, Pezzoli G, Lees A, Shaw K, Cubo E, Martinez-Martin P, Rascol O, Negre-Pages L, Senard A, Schwarz J, Strecker K, Reichmann H, Storch A, Löhle M, Stocchi F, Grosset K: Adherence to antiparkinson medication in a multicenter European study. *Mov Disord*. 2009 Apr 30;24(6):826-32
153. **Antonini A**, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH: A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. *Lancet Neurol*. 2009 Oct;8(10):929-37
154. **Antonini A**, Odin P. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. *Parkinsonism Relat Disord*. 2009 Dec;15 Suppl 4:S97-100
155. **Antonini A**: Imaging for early differential diagnosis of parkinsonism. *Lancet Neurol*. 2010 Feb;9(2):130-1
156. Zangaglia R, Stocchi F, Sciarretta M, **Antonini A**, Mancini F, Guidi M, Martignoni E, Pacchetti C: Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study. *Clin Neuropharmacol*. 2010 Mar-Apr;33(2):61-6
157. Sironi F, Trotta L, **Antonini A**, Zini M, Ciccone R, Della Mina E, Meucci N, Sacilotto G, Primignani P, Brambilla T, Coviello DA, Pezzoli G, Goldwurm S: alpha-Synuclein multiplication analysis in Italian familial Parkinson disease. *Parkinsonism Relat Disord*. 2010 Mar;16(3):228-31.
158. Siri C, Cilia R, De Gaspari D, Villa F, Goldwurm S, Marco C, Pezzoli G, **Antonini A**: Psychiatric symptoms in Parkinson's disease assessed with the SCL-90R self-reported questionnaire. *Neurol Sci*. 2010 Feb;31(1):35-40. Epub 2009 Oct 6
159. Pezzoli G, Tesei S, Canesi M, Sacilotto G, Vittorio M, Mizuno Y, Mochizuki H, **Antonini A**: The effect of repeated administrations of granulocyte colony stimulating factor for blood stem cells mobilization in patients with progressive supranuclear palsy, corticobasal degeneration and multiple system atrophy. *Clin Neurol Neurosurg*. 2010 Jan;112(1):65-7. Epub 2009 Sep 17
160. Cilia R, Marotta G, Landi A, Isaias IU, Mariani CB, Vergani F, Benti R, Sganzerla E, Pezzoli G, **Antonini A**. Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson's disease: a prospective case-control study. *Clin Neurol Neurosurg*. 2009 Feb;111(2):140-6
161. Siri C, Cilia R, De Gaspari D, Canesi M, Meucci N, Zecchinelli AL, Pezzoli G, **Antonini A**: Cognitive status of patients with Parkinson's disease and pathological gambling. *J Neurol*. 2010 Feb;257(2):247-52
162. Colosimo C, Morgante L, **Antonini A**, Barone P, et al: PRIAMO STUDY GROUP. Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. *J Neurol*. 2010 Jan;257(1):5-14.
163. **Antonini A**, Chaudhuri KR, Martinez-Martin P, Odin P. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease. *CNS Drugs*. 2010 Feb 1;24(2):119-29
164. Cilia R, Ko JH, Cho SS, van Eimeren T, Marotta G, Pellecchia G, Pezzoli G, **Antonini A**, Strafella AP: Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. *Neurobiol Dis*. 2010 Mar 22
165. Isaias IU, Marotta G, Hirano S, Canesi M, Benti R, Righini A, Tang C, Cilia R, Pezzoli G, Eidelberg D, **Antonini A**: Imaging Essential tremor. *Mov Disord*. 2010 Apr 30;25(6):679-86
166. Zanettini R, **Antonini A**, Gatto G, Gentile R, Tesei S, Pezzoli G. Regression of Cardiac Valvulopathy Related to Ergot-Derived Dopamine Agonists. *Cardiovasc Ther*. 2010 Jun 11
167. **Antonini A**, Bondiolotti G, Natuzzi F, Bareggi SR Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. *Eur Neuropsychopharmacol*. 2010; 20(10):683-7
168. Isaias IU, **Antonini A**: Single-Photon Emission Computed Tomography in Diagnosis and Differential Diagnosis of Parkinson's Disease. *Neurodegener Dis*. 2010 Jul 12;7(5):319-329
169. **Antonini A**, Bernardi L, Calandrella D, Mancini F, Plebani M Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders. *Funct Neurol*. 2010 Jan-Mar;25(1):21-5
170. Santangelo G, Vitale C, Trojano L, De Gaspari D, Bilo L, **Antonini A**, Barone P. Differential neuropsychological profiles in Parkinsonian patients with or without vascular lesions. *Mov Disord*. 2010 15;25(1):50-6
171. Bovi T, **Antonini A**, Ottaviani S, Antonioli A, Cecchini MP, Di Francesco V, Bassetto MA, Zamboni M, Fiaschi A, Moretto G, Sbarbati A, Tinazzi M, Osculati F: The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. *J Neurol*. 2010 Jul 16
172. **Antonini A**, Barone P, Ceravolo R: Role of pramipexole in the management of Parkinson's disease. *CNS Drugs* 2010 24:829-841
173. Fantini ML, Cossu G, Molari A, Cabinio M, Uyanik O, Cilia R, Melis M, **Antonini A**, Ferini-Strambi L: Sleep in genetically confirmed pantothenate kinase-associated neurodegeneration: a video-polysomnographic study *Parkinsons Dis*. 2010 Jun 29;2010:342834.
174. Metta V, Logishetty K, Martinez-Martin P, Gage HM, Schartau PE, Kaluarachchi TK, Martin A, Odin P, Barone P, Stocchi F, **Antonini A**, Chaudhuri KR: The possible clinical predictors of fatigue in Parkinson's disease: a study of 135 patients as part of international nonmotor scale validation project. *Parkinsons Dis*. 2011;2011:125271.
175. Vergani F, Landi A, Pirillo D, Cilia R, **Antonini A**, Sganzerla EP Surgical, medical and hardware adverse events in a series of 141 patients undergoing subthalamic deep brain stimulation for Parkinson disease. *World Neurosurg* 2010; 73:338-344
176. Mure H, Hirano S, Tang CC, Isaias IU, **Antonini A**, Ma Y, Dhawan V, Eidelberg D: Parkinson's disease tremor-related network: characterization, progression and treatment effects. *Neuroimage* 2011; 54:1244-53
177. Poewe W, **Antonini A**, Zijlmans JC, Burkhard PR, Vingerhoets F.: Levodopa in the treatment of Parkinson's disease: an old drug still going strong. *Clin Interv Aging* 2010; 5: 229-238
178. **Antonini A**, Isaias IU, Rodolfi G, Landi A, Natuzzi F, Siri C, Pezzoli G: A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. *J Neurol* 2011; 258:579-85

179. D'Agostino A, De Gaspari D, **Antonini A**, Kantzas I, Limosani I, Manzone ML, Schiavella M, Paganini L, Siri C, Rizzi P, Scarone S: Cognitive bizarreness in the dream and waking mentation of nonpsychotic patients with Parkinson's disease *J Neuropsychiatry Clin Neurosci*. 2010;22(4):395-400
180. **Antonini A**, Ursino G, Calandrella D, Bernardi D, Plebani M Continuous dopaminergic delivery in Parkinson's disease. *J Neurol* 2010; 257 (Suppl 2):S305-S308
181. Landi A, Pirillo D, Cilia R, **Antonini A**, Sganzerla EP: Cortical visual evoked potentials recorded after optic tract near field stimulation during GPI-DBS in non-cooperative patients. *Clin Neurol Neurosurg*. 2011;113(2):119-22.
182. Hilker R, **Antonini A**, Odin P: What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus? *J Neural Transm*. 2011; Jun;118(6):907-14
183. **Antonini A**, Siri C, Santangelo G, Cilia R, Poletti M, Canesi M, Caporal A, Mancini F, Pezzol G, Ceravolo R, Bonuccelli U, Barone P Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. *Mov Disord* 2011; 15;26(3):464-8
184. Cilia R, Cho SS, van Eimeren T, Marotta G, Siri C, Ko JH, Pellecchia G, Pezzoli G, **Antonini A**, Strafella AP: Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: A path modeling analysis. *Mov Disord*. 2011; 26(2):225-33
185. Moreno-López C, Santamaría J, Salameo M, Del Sorbo F, Albanese A, Pellecchia MT, Barone P, Overeem S, Bloem B, Aarden W, Canesi M, **Antonini A**, et al: Excessive Daytime Sleepiness in Multiple System Atrophy (SLEEMSA Study). *Arch Neurol*. 2011; Feb;68(2):223-30
186. Vallelunga A, Flaibani R, Formento-Dojot P, Biundo R, Facchini S, **Antonini A**: Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. *Parkinsonism Relat Disord*. 2011; 18(4):397-9.
187. Westin J, Schiavella M, Memedi M, Nyholm D, Dougherty M, **Antonini A**: Validation of a home environment test battery for supporting assessments in advanced Parkinson's disease. *Neurol Sci*. 2012 Aug;33(4):831-8
188. Marconi R, **Antonini A**, Barone P, Colosimo C, Avarello TP, Bottacchi E, Cannas A, Ceravolo MG, Ceravolo R, Cicarelli G, Gaglio RM, Giglia L, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrala R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Del Dotto P, De Gaspari D, Grasso L, Morgante F, Santangelo G, Fabbri G, Morgante L: Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. *Neurol Sci*. 2012 Jun;33(3):585-93
189. **Antonini A**, Calandrella D. Pharmacokinetic evaluation of pramipexole. *Expert Opin Drug Metab Toxicol*. 2011 Oct;7(10):1307-14
190. Biundo R, Formento-Dojot P, Facchini S, Vallelunga A, Ghezzi L, Foscolo L, Meneghello F, **Antonini A**: Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities. *J Neurol Sci*. 2011 Nov 15;310(1-2):64-9
191. Morgante L, Colosimo C, **Antonini A**, Marconi R, Meco G, Pederzoli M, Pontieri FE, Cicarelli G, Abbruzzese G, Zappulla S, Ramat S, Manfredi M, Bottacchi E, Abrignani M, Berardelli A, Cozzolino A, Paradiso C, De Gaspari D, Morgante F, Barone P: On behalf of the PRIAMO Study Group. Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. *J Neurol Neurosurg Psychiatry*. 2012 Jan;83(1):76-82
192. **Antonini A**, Martinez-Martin P, Chaudhuri RK, Merello M, Hauser R, Katzenschlager R, Odin P, Stacy M, Stocchi F, Poewe W, Rascol O, Sampaio C, Schrag A, Stebbins GT, Goetz CG: Wearing-off scales in Parkinson's disease: Critique and recommendations. *Mov Disord*. 2011 Oct;26(12):2169-75
193. Chaudhuri KR, Odin P, **Antonini A**, Martinez-Martin P. Parkinson's disease: The non-motor issues. *Parkinsonism Relat Disord*. 2011 Dec;17(10):717-23
194. Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovцова J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P; PSP Genetics Study Group, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U, Schellenberg GD, Albin RL, Alonso E, **Antonini A**, Apfelbacher M, Arnold SE, Avila J, Beach TG, Beecher S, Berg D, Bird TD, Bogdanovic N, Boon AJ, Bordonon Y, Brice A et al.: Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. *Nat Genet*. 2011 Jun 19;43(7):699-705
195. **Antonini A**, Calandrella D. Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients. *Neuropsychiatr Dis Treat*. 2011;7:297-302. Epub 2011 May 15
196. Calandrella D, **Antonini A**: Pathological gambling in Parkinson's disease: disease related or drug related? *Expert Rev Neurother*. 2011 Jun;11(6):809-14. Review
197. Cilia R, Rossi C, Frosini D, Volterrani D, Siri C, Pagni C, Benti R, Pezzoli G, Bonuccelli U, **Antonini A**, Ceravolo R: Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. *PLoS One*. 2011 May 2;6(5):e18301
198. **Antonini A**: The conundrum of neuroprotection in Parkinson's disease. *Lancet Neurol*. 2011 May;10(5):396-7
199. Pellecchia MT, **Antonini A**, Bonuccelli U, Fabbri G, Ferini Strambi L, Stocchi F, Battaglia A, Barone P: Observational study of sleep-related disorders in Italian patients with Parkinson's disease: usefulness of the Italian version of Parkinson's disease sleep scale. *Neurol Sci*. 2012 Jun;33(3):689-94
200. **Antonini A**, Pilleri M, Padoan A, Landi A, Ferla S, Biundo R, D'Avella D: Successful subthalamic stimulation in genetic Parkinson's disease caused by duplication of the α -synuclein gene. *J Neurol*. 2012 Jan;259(1):165-7
201. Martinez-Martin P, Falup Pecurariu C, Odin P, van Hilten JJ, **Antonini A**, Rojo-Abuin JM, Borges V, Trenkwalder C, Aarsland D, Brooks DJ, Ray Chaudhuri K: Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. *J Neurol*. 2012; 259(8):1639-47
202. Storch A, Csoti I, Eggert K, Henriksen T, Plate A, Lorrain M, Oertel WH, **Antonini A**: Intrathecal application of autologous bone marrow cell preparations in parkinsonian syndromes. *Mov Disord*. 2012; 27(12):1552-5

203. Abbruzzese G, **Antonini A**, Barone P, Stocchi F, Tamburini T, Bernardi L, Amboni M, Vacca L, Posocco V, Colombo D: Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson's disease. *Neurol Sci*. 2012; 33(6):1319-27
204. **Antonini A**, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U, Abbruzzese G, Ramat S, Petrone A, Quatrala R, Marconi R, Ceravolo R, Stefani A, Lopiano L, Zappia M, Capus L, Morgante L, Tamma F, Tinazzi M, Colosimo C, Guerra UP: The relationship between cerebral vascular disease and parkinsonism: The VADO study. *Parkinsonism Relat Disord*. 2012 Jul;18(6):775-80
205. **Antonini A**: Movement disorders: towards new therapies in Parkinson's disease. *The Lancet Neurology* 01/2012; 11(1):7-8
206. **Antonini A**, Abbruzzese G, Ferini-Strambi L, Tilley B, Huang J, Stebbins GT, Goetz CG, Barone P; MDS-UPDRS Italian Validation Study Group, Bandettini di Poggio M, Fabbrini G, Di Stasio F, Tinazzi M, Bovi T, Ramat S, Meoni S, Pezzoli G, Canesi M, Martinelli P, Maria Scaglione CL, Rossi A, Tambasco N, Santangelo G, Picillo M, Morgante L, Morgante F, Quatrala R, Sensi M, Pilleri M, Biundo R, Nordera G, Caria A, Pacchetti C, Zangaglia R, Lopiano L, Zibetti M, Zappia M, Nicoletti A, Quattrone A, Salsone M, Cossu G, Murgia D, Albanese A, Del Sorbo F: Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. *Neurol Sci*. 2013 May;34(5):683-7.
207. **Antonini A**, Barone P, Marconi R, Morgante L, Zappulla S, Pontieri FE, Ramat S, Ceravolo MG, Meco G, Cicarelli G, Pederzoli M, Manfredi M, Ceravolo R, Mucchiut M, Volpe G, Abbruzzese G, Bottacchi E, Bartolomei L, Ciacci G, Cannas A, Randisi MG, Petrone A, Baratti M, Toni V, Cossu G, Del Dotto P, Bentivoglio AR, Abrignani M, Scala R, Pennisi F, Quatrala R, Gaglio RM, Nicoletti A, Perini M, Avarello T, Pisani A, Scaglioni A, Martinelli PE, Iemolo F, Ferigo L, Simone P, Soliveri P, Troianiello B, Consoli D, Mauro A, Lopiano L, Nastasi G, Colosimo C: The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. *J Neurol*. 2012 Dec;259(12):2621-31
208. Reddy P, Martinez-Martin P, Rizos A, Martin A, Faye GC, Forgacs I, Odin P, **Antonini A**, Chaudhuri KR: Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. *Clin Neuropharmacol*. 2012 Sep-Oct;35(5):205-7.
209. Pilleri M, Facchini S, Gasparoli E, Biundo R, Bernardi L, Marchetti M, Formento P, **Antonini A**: Cognitive and MRI correlates of orthostatic hypotension in Parkinson's disease. *J Neurol*. 2013 Jan;260(1):253-9.
210. Mazza A, Ravenni R, **Antonini A**, Casiglia E, Rubello D, Pauletto P: Arterial hypertension, a tricky side of Parkinson's disease: physiopathology and therapeutic features. *Neurol Sci*. 2013 May;34(5):621-7.
211. Aguirregomozcorta M, Stamelou M, **Antonini A**, Schwingenschuh P, Prvulovich L, Edwards MJ, Dickson JC, Bhatia KP: Patients with rest-tremor and scans with ipsilateral dopaminergic deficit. *J Neurol*. 2013 Apr;260(4):1132-5.
212. Landi A, Trezza A, Pirillo D, Vimercati A, **Antonini A**, Sganzerla EP: Spinal cord stimulation for the treatment of sensory symptoms in advanced Parkinson's disease. *Neuromodulation*. 2013 May-Jun;16(3):276-9.
213. Pilleri M, Koutsikos K, **Antonini A**: Is there room for new non-dopaminergic treatments in Parkinson's disease? *J Neural Transm*. 2013 Feb;120(2):349-52.
214. Berardelli A, Wenning GK, **Antonini A**, Berg D, Bloem BR, Bonifati V, Brooks D, Burn DJ, Colosimo C, Fanciulli A, Ferreira J, Gasser T, Grandas F, Kanovsky P, Kostic V, Kulisevsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Schrag A, Seppi K, Taba P, Vidailhet M: EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. *Eur J Neurol*. 2013 Jan;20(1):16-34.
215. Volkman J, Albanese A, **Antonini A**, Chaudhuri KR, Clarke CE, de Bie RM, Deuschl G, Eggert K, Houeto JL, Kulisevsky J, Nyholm D, Odin P, Østergaard K, Poewe W, Pollak P, Rabey JM, Rascol O, Ruzicka E, Samuel M, Speelman H, Sydow O, Valldeoriola F, van der Linden C, Oertel W: Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. *J Neurol*. 2013 Nov;260(11):2701-14.
216. **Antonini A**, Albin RL: Dopaminergic treatment and nonmotor features of Parkinson disease: the horse lives. *Neurology*. 2013 Feb 26;80(9):784-5.
217. Onofrij M, Varanese S, Bonanni L, Taylor JP, **Antonini A**, Valente EM, Petrucci S, Stocchi F, Thomas A, Perfetti B: Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies. *J Neurol*. 2013 Jul;260(7):1731-42.
218. Isella V, Mapelli C, Morielli N, De Gaspari D, Siri C, Pezzoli G, **Antonini A**, Poletti M, Bonuccelli U, Picchi L, Napolitano A, Vista M, Greco A, Appollonio IM: Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinson's disease. *Neurol Sci*. 2013 Oct;34(10):1751-8.
219. Ceravolo R, Rossi C, Cilia R, Tognoni G, **Antonini A**, Volterrani D, Bonuccelli U: Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: a SPECT follow-up study. *Parkinsonism Relat Disord*. 2013 May;19(5):557-9. doi: 10.1016/j.parkreldis.2013.01.013
220. Müller T, van Laar T, Cornblath DR, Odin P, Klostermann F, Grandas FJ, Ebersbach G, Urban PP, Valldeoriola F, **Antonini A**: Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. *Parkinsonism Relat Disord*. 2013 May;19(5):501-7
221. Siri C, Duerr S, Canesi M, Delazer M, Esselink R, Bloem BR, Gurevich T, Balas M, Giladi N, Santacruz P, Marti F, Tolosa E, Rubino A, Meco G, Poewe W, Pezzoli G, Wenning G, **Antonini A**: A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. *J Neural Transm*. 2013 Apr;120(4):613-8.
222. Ray Chaudhuri K, Rojo JM, Schapira AH, Brooks DJ, Stocchi F, Odin P, **Antonini A**, Brown RJ, Martinez-Martin P: A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. *PLoS One*. 2013;8(2):e57221.
223. Biundo R, Weis L, Pilleri M, Facchini S, Formento-Dojot P, Vallelunga A, **Antonini A**: Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson's disease. *J Neural Transm*. 2013 Apr;120(4):627-33.

224. Ray Chaudhuri K, Martinez-Martin P, **Antonini A**, Brown RG, Friedman JH, Onofrj M, Surmann E, Ghys L, Trenkwalder C: Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. *Parkinsonism Relat Disord*. 2013 Jul;19(7):660-5.
225. **Antonini A**, Odin P, Lopiano L, Tomantschger V, Pacchetti C, Pickut B, Gasser UE, Calandrella D, Mancini F, Zibetti M, Minafra B, Bertaina I, De Deyn P, Cras C, Wolf E, Spielberger S, Poewe W: Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. *J Neural Transm*. 2013 Nov;120(11):1553-8.
226. Zambito Marsala S, Vitaliani R, Volpe D, Capozzoli F, Baroni L, Belgrado E, Borsato C, Gioulis M, Marchini C, **Antonini A**: Rapid onset of efficacy of rasagiline in early Parkinson's disease. *Neurol Sci*. 2013 Nov;34(11):2007-13.
227. Biundo R, Calabrese M, Weis L, Facchini S, Ricchieri G, Gallo P, **Antonini A**: Anatomical correlates of cognitive functions in early Parkinson's disease patients. *PLoS One*. 2013 May 22;8(5):e64222
228. Fabbrini G, Abbruzzese G, Barone P, **Antonini A**, Tinazzi M, Castegnaro G, Rizzoli S, Morisky DE, Lessi P, Ceravolo R: REASON study group. Adherence to anti-Parkinson drug therapy in the "REASON" sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the "Morisky Medical Adherence Scale-8 items". *Neurol Sci*. 2013 Nov;34(11):2015-22
229. Isella V, Mapelli C, Morielli N, De Gaspari D, Siri C, Pezzoli G, **Antonini A**, Poletti M, Bonuccelli U, Picchi L, Napolitano A, Vista M, Veglia M, Piamarta F, Grassi F, Appollonio IM: Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease- Cognition (SCOPA-Cog). *Funct Neurol*. 2013 Apr-May;28(2):121-5.
230. Mancini F, Comi C, Oggioni GD, Pacchetti C, Calandrella D, Coletti Moja M, Riboldazzi G, Tunesi S, Dal Fante M, Manfredi L, Lacerenza M, Cantello R, **Antonini A**: Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. *Parkinsonism Relat Disord*. 2014 Jan;20(1):27-31
231. Isella V, Mapelli C, Siri C, De Gaspari D, Pezzoli G, **Antonini A**, Poletti M, Bonuccelli U, Vista M, Appollonio IM: Validation and attempts of revision of the MDS-recommended tests for the screening of Parkinson's disease dementia. *Parkinsonism Relat Disord*. 2014 Jan;20(1):32-6
232. Vallelunga A, Pegoraro V, Pilleri M, Biundo R, De Iulius A, Marchetti M, Facchini S, Formento Dojot P, **Antonini A**: The MTHFR C677T polymorphism modifies age at onset in Parkinson's disease. *Neurol Sci*. 2014 Jan;35(1):73-7.
233. Isella V, Mapelli C, Morielli N, Siri C, De Gaspari D, Pezzoli G, **Antonini A**, Poletti M, Bonuccelli U, Picchi L, Napolitano A, Vista M, Appollonio IM: Diagnosis of possible Mild Cognitive Impairment in Parkinson's disease: Validity of the SCOPA-Cog. *Parkinsonism Relat Disord*. 2013 Dec;19(12):1160-3.
234. Tinazzi M, Abbruzzese G, **Antonini A**, Ceravolo R, Fabbrini G, Lessi P, Barone P: REASON Study Group. Reasons driving treatment modification in Parkinson's disease: Results from the cross-sectional phase of the REASON study. *Parkinsonism Relat Disord*. 2013 Dec;19(12):1130-5.
235. Pilleri M, Levedianos G, Weis L, Gasparoli E, Facchini S, Biundo R, Formento-Dojot P, **Antonini A**: Heart rate circadian profile in the differential diagnosis between Parkinson disease and multiple system atrophy. *Parkinsonism Relat Disord*. 2014 Feb;20(2):217-21
236. Stocchi F, **Antonini A**, Barone P, Tinazzi M, Zappia M, Onofrj M, Ruggieri S, Morgante L, Bonuccelli U, Lopiano L, Pramstaller P, Albanese A, Attar M, Posocco V, Colombo D, Abbruzzese G: DEEP study group. Early DEtection of wEaring off in Parkinson disease: The DEEP study. *Parkinsonism Relat Disord*. 2014 Feb;20(2):204-11
237. Santangelo G, Barone P, Abbruzzese G, Ferini-Strambi L, **Antonini A**: Validation of the Italian version of Parkinson's Disease-Cognitive Rating Scale (PD-CRS). *Neurol Sci*. 2014 Apr;35(4):537-44
238. **Antonini A**, Calandrella D, Merello M, Koutsikos K, Pilleri M: Effects of rotigotine on Parkinson's disease-related sleep disturbances. *Expert Opin Pharmacother*. 2013 Dec;14(18):2571-80.
239. Biundo R, Weis L, Pilleri M, Facchini S, Formento-Dojot P, Vallelunga A, **Antonini A**: Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson's disease. *J Neural Transm*. 2013 Apr;120(4):627-33.
240. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanaganas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, **Antonini A**: for the LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. *Lancet Neurol*. 2014 Feb;13(2):141-9
241. Pilleri M, **Antonini A**: Novel levodopa formulations in the treatment of Parkinson's disease. *Expert Rev Neurother*. 2014;14(2):143-9.
242. Vallelunga A, Ragusa M, Di Mauro S, Iannitti T, Pilleri M, Biundo R, Weis L, Di Pietro C, De Iulius A, Nicoletti A, Zappia M, Purrello M, **Antonini A**: Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy. *Front Cell Neurosci*. 2014 Jun 10;8:156.
243. Krismer F, Jellinger KA, Scholz SW, Seppi K, Stefanova N, **Antonini A**, Poewe W, Wenning GK: Multiple system atrophy as emerging template for accelerated drug discovery in α -synucleinopathies. *Parkinsonism Relat Disord*. 2014 May 21. pii: S1353-8020(14)00194-1
244. Stankovic I, Krismer F, Jesic A, **Antonini A**, Benke T, Brown RG, Burn DJ, Holton JL, Kaufmann H, Kostic VS, Ling H, Meissner WG, Poewe W, Semnic M, Seppi K, Takeda A, Weintraub D, Wenning GK: Movement Disorders Society MSA (MODIMSA) Study Group. Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. *Mov Disord*. 2014 Jun;29(7):857-67
245. Braga M, Pederzoli M, **Antonini A**, Beretta F, Crespi V: Reasons for hospitalization in Parkinson's disease: a case-control study. *Parkinsonism Relat Disord*. 2014 May;20(5):488-92;

246. Biundo R, Weis L, Facchini S, Formento-Dojot P, Vallelunga A, Pilleri M, **Antonini A**: Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia. *Parkinsonism Relat Disord*. 2014 Apr;20(4):394-9.
247. Rektorova I, Biundo R, Marecek R, Weis L, Aarsland D, **Antonini A**: Grey matter changes in cognitively impaired Parkinson's disease patients. *PLoS One*. 2014 Jan 21;9(1):e85595.
248. **Antonini A**, Biundo R Parkinson disease: Can dopamine transporter imaging define early PD? *Nat Rev Neurol*. 2014 Jul 8. doi: 10.1038/nrneuro.2014.123.
249. **Antonini A**, Poewe W: Adenosine A2A receptor antagonists in Parkinson's disease: still in the running. *Lancet Neurol*. 2014 Aug;13(8):748-9
250. Comi C, Magistrelli L, Oggioni GD, Carecchio M, Fleetwood T, Cantello R, Mancini F, **Antonini A**. Peripheral nervous system involvement in Parkinson's disease: evidence and controversies. *Parkinsonism Relat Disord*. 2014 Dec;20(12):1329-34.
251. Rizos A, Martinez-Martin P, Odin P, **Antonini A**, Kessel B, Kozul TK, Todorova A, Douiri A, Martin A, Stocchi F, Dietrichs E, Chaudhuri KR; EUROPAR and the IPDMS non-Motor PD Study Group. Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: an international multicenter study. *Parkinsonism Relat Disord*. 2014 Nov;20(11):1231-5.
252. Colombo D, Abbruzzese G, **Antonini A**, Barone P, Bellia G, Franconi F, Simoni L, Attar M, Zagni E, Haggia G, Stocchi F. The "gender factor" in wearing-off among patients with Parkinson's disease: a post hoc analysis of DEEP study. *ScientificWorldJournal*. 2015;2015:787451
253. Poewe W, **Antonini A**. Novel formulations and modes of delivery of levodopa. *Mov Disord*. 2015 Jan;30(1):114-20.
254. Caminiti SP, Siri C, Guidi L, **Antonini A**, Perani D. The neural correlates of spatial and object working memory in elderly and Parkinson's disease subjects. *Behav Neurol*;2015:123636
255. Samuel M, Rodriguez-Oroz M, **Antonini A**, Brotchie JM, Ray Chaudhuri K, Brown RG, Galpern WR, Nirenberg MJ, Okun MS, Lang AE. Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. *Mov Disord*. 2015 Feb;30(2):150-9.
256. Poewe W, Seppi K, Fitzer-Attas CJ, Wenning GK, Gilman S, Low PA, Giladi N, Barone P, Sampaio C, Eyal E, Rascol O; Rasagiline-for-MSA investigators. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. *Lancet Neurol*. 2015 Feb;14(2):145-52.
257. Stathis P, Konitsiotis S, **Antonini A**. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias. *Expert Rev Neurother*. 2015 Feb;15(2):207-13.
258. Pilleri M, **Antonini A**. Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease. *Expert Opin Drug Saf*. 2015 Feb;14(2):281-94.
259. **Antonini A**, Yegin A, Preda C, Bergmann L, Poewe W; GLORIA study investigators and coordinators. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. *Parkinsonism Relat Disord*. 2015 Mar;21(3):231-5
260. Chaudhuri KR, Sauerbier A, Rojo JM, Sethi K, Schapira AH, Brown RG, **Antonini A**, Stocchi F, Odin P, Bhattacharya K, Tsuboi Y, Abe K, Rizos A, Rodriguez-Blazquez C, Martinez-Martin P. The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: a simple grading system. *Parkinsonism Relat Disord*. 2015 Mar;21(3):287-91
261. Martinez-Martin P, Reddy P, Katzenschlager R, **Antonini A**, Todorova A, Odin P, Henriksen T, Martin A, Calandrella D, Rizos A, Bryndum N, Glad A, Dafsari HS, Timmermann L, Ebersbach G, Kramberger MG, Samuel M, Wenzel K, Tomantschger V, Storch A, Reichmann H, Pirtosek Z, Trost M, Svenningsson P, Palhagen S, Volkmann J, Chaudhuri KR. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. *Mov Disord*. 2015 Apr;30(4):510-6.
262. Biundo R, Weis L, Facchini S, Formento-Dojot P, Vallelunga A, Pilleri M, Weintraub D, **Antonini A**. Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. *Mov Disord*. 2015 Apr 15;30(5):688-95
263. Amboni M, Stocchi F, Abbruzzese G, Morgante L, Onofri M, Ruggieri S, Tinazzi M, Zappia M, Attar M, Colombo D, Simoni L, Ori A, Barone P, **Antonini A**; DEEP Study Group. Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study. *Parkinsonism Relat Disord*. 2015 Jun;21(6):644-9
264. Abbruzzese G, Barone P, Ceravolo R, Fabbrini G, Lessi P, Ori A, Simoni L, Tinazzi M, **Antonini A**. Clinical variables associated with treatment changes in Parkinson's disease: results from the longitudinal phase of the REASON study. *Neurol Sci*. 2015 Jun;36(6):935-43
265. Ceravolo R, **Antonini A**, Frosini D, De Iulius A, Weis L, Cecchin D, Tosetti M, Bonuccelli U, Cosottini M. Nigral anatomy and striatal denervation in genetic Parkinsonism: A family report. *Mov Disord*. 2015 Jul;30(8):1148-
266. Franciotti R, Delli Pizzi S, Perfetti B, Tartaro A, Bonanni L, Thomas A, Weis L, Biundo R, **Antonini A**, Onofri M. Default mode network links to visual hallucinations: A comparison between Parkinson's disease and multiple system atrophy. *Mov Disord*. 2015 Aug;30(9):1237-47
267. Barone P, Santangelo G, Morgante L, Onofri M, Mecocci G, Abbruzzese G, Bonuccelli U, Cossu G, Pezzoli G, Stanzione P, Lopiano L, **Antonini A**, Tinazzi M. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients. *Eur J Neurol*. 2015 Aug;22(8):1184-91.
268. Pilleri M, Weis L, Zabeo L, Koutsikos K, Biundo R, Facchini S, Rossi S, Masiero S, **Antonini A**. Overground robot assisted gait trainer for the treatment of drug-resistant freezing of gait in Parkinson disease. *J Neurol Sci*. 2015 Aug 15;355(1-2):75-8

269. Cossu G, Ricchi V, Pilleri M, Mancini F, Murgia D, Ricchieri G, Mereu A, Melis M, **Antonini A**. Levodopa-carbidopa intrajejunal gel in advanced Parkinson disease with "on" freezing of gait. *Neurol Sci*. 2015 Sep;36(9):1683-6
270. Timpka J, Fox T, Fox K, Honig H, Odin P, Martinez-Martin P, **Antonini A**, Ray Chaudhuri K. Improvement of dyskinesias with l-dopa infusion in advanced Parkinson's disease. *Acta Neurol Scand*. 2015 Sep 11
271. Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, Krauss JK, Henriksen T, Katzenschlager R, **Antonini A**, Rascol O, Poewe W; National Steering Committees. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. *Parkinsonism Relat Disord*. 2015 Oct;21(10):1133-44.
272. Auzou N, Dujardin K, Biundo R, Foubert-Samier A, Barth C, Duval F, Tison F, Defebvre L, **Antonini A**, Meissner WG. Diagnosing dementia in multiple system atrophy by applying Movement Disorder Society diagnostic criteria for Parkinson's disease dementia. *Parkinsonism Relat Disord*. 2015 Oct;21(10):1273-7
273. Chaudhuri KR, Rizos A, Trenkwalder C, Rascol O, Pal S, Martino D, Carroll C, Paviour D, Falup-Pecurariu C, Kessel B, Silverdale M, Todorova A, Sauerbier A, Odin P, **Antonini A**, Martinez-Martin P; EUROPAR and the IPMDS Non Motor PD Study Group. King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. *Mov Disord*. 2015 Oct;30(12):1623-31
274. **Antonini A**, Bauer L, Dohin E, Oertel WH, Rascol O, Reichmann H, Schmid M, Singh P, Tolosa E, Chaudhuri KR. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial. *Eur J Neurol*. 2015 Oct;22(10):1400-7
275. Biundo R, Weis L, Fiorenzato E, Gentile G, Giglio M, Schifano R, Campo MC, Marcon V, Martinez-Martin P, Bisiacchi P, **Antonini A**. Double-blind Randomized Trial of tDCS Versus Sham in Parkinson Patients With Mild Cognitive Impairment Receiving Cognitive Training. *Brain Stimul*. 2015 Nov-Dec;8(6):1223-5
276. Indelicato E, Fanciulli A, Poewe W, **Antonini A**, Pontieri FE, Wenning GK. Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy. *Parkinsonism Relat Disord*. 2015 Dec;21(12):1393-7
277. **Antonini A**, Tinazzi M. Targeting pain in Parkinson's disease. *Lancet Neurol*. 2015 Dec;14(12):1144-5
278. Vorovenci RJ, **Antonini A**. The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson's disease. *Expert Rev Neurother*. 2015 Dec;15(12):1383-90
279. Araújo R, Ferreira JJ, **Antonini A**, Bloem BR. "Gunslinger's gait": a new cause of unilaterally reduced arm swing. *BMJ*. 2015 Dec 14;351:h6141
280. Ossig C, **Antonini A**, Buhmann C, Classen J, Csoti I, Falkenburger B, Schwarz M, Winkler J, Storch A. Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease. *J Neural Transm (Vienna)*. 2016 Jan;123(1):57-64
281. Vorovenci RJ, Biundo R, **Antonini A**. Therapy-resistant symptoms in Parkinson's disease. *J Neural Transm (Vienna)*. 2016 Jan;123(1):19-30
282. Preda F, Cavandoli C, Lettieri C, Pilleri M, **Antonini A**, Eleopra R, Mondani M, Martinuzzi A, Sarubbo S, Ghisellini G, Trezza A, Cavallo MA, Landi A, Sensi M. Switching from constant voltage to constant current in deep brain stimulation: a multicenter experience of mixed implants for movement disorders. *Eur J Neurol*. 2016 Jan;23(1):190-5
283. Dafsari HS, Reddy P, Herchenbach C, Wawro S, Petry-Schmelzer JN, Visser-Vandewalle V, Rizos A, Silverdale M, Ashkan K, Samuel M, Evans J, Huber CA, Fink GR, **Antonini A**, Chaudhuri KR, Martinez-Martin P, Timmermann L; IPMDS Non-Motor Symptoms Study Group. Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease. *Brain Stimul*. 2016 Jan-Feb;9(1):78-85
284. Biundo R, Weis L, Bostantjopoulou S, Stefanova E, Falup-Pecurariu C, Kramberger MG, Geurtsen GJ, **Antonini A**, Weintraub D, Aarsland D. MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. *J Neural Transm (Vienna)*. 2016 Apr;123(4):431-8
285. Vesely B, **Antonini A**, Rektor I. The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature. *J Neural Transm (Vienna)*. 2016 Mar;123(3):241-50
286. Kimber T, **Antonini A**. Peripheral neuropathy and levodopa therapy in Parkinson disease: novel insights. *Eur J Neurol*. 2016 Mar;23(3):435-6
287. **Antonini A**, Fung VS, Boyd JT, Slevin JT, Hall C, Chatamra K, Eaton S, Benesh JA. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients. *Mov Disord*. 2016 Apr;31(4):530-7
288. Fabbri M, Coelho M, Abreu D, Guedes LC, Rosa MM, Costa N, **Antonini A**, Ferreira JJ. Do patients with late-stage Parkinson's disease still respond to levodopa? *Parkinsonism Relat Disord*. 2016 May;26:10-6
289. Rizos A, Sauerbier A, **Antonini A**, Weintraub D, Martinez-Martin P, Kessel B, Henriksen T, Falup-Pecurariu C, Silverdale M, Durner G, Røkenes Karlens K, Grilo M, Odin P, Chaudhuri KR; EUROPAR and the IPMDS Non-Motor-PD-Study Group. A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. *Eur J Neurol*. 2016 Aug;23(8):1255-61
290. Biundo R, Weis L, **Antonini A**. tDCS effect on cognitive performance in Parkinson's disease. *Mov Disord*. 2016 Aug;31(8):1253-4
291. Fiorenzato E, Weis L, Falup-Pecurariu C, Diaconu S, Siri C, Reali E, Pezzoli G, Bisiacchi P, **Antonini A**, Biundo R. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy. *J Neural Transm (Vienna)*. 2016 Jun 22
292. Trezza A, **Antonini A**, Sganzerla EP, Landi A. Globus pallidus internus deep brain stimulation for the treatment of status dystonicus in tardive dystonia. *Acta Neurochir (Wien)*. 2016 Sep;158(9):1789-91
293. Lopiano L, Modugno N, Marano P, Sensi M, Meo G, Cannas A, Gusmaroli G, Tamma F, Mancini F, Quatraro R, Costanzo AM, Gualberti G, Melzi G, di Luzio Paparatti U, **Antonini A**. Motor outcomes in patients with

- advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study. *Neurol Sci*. 2016 Nov;37(11):1785-1792
294. **Antonini A**, Chaudhuri KR, Boroojerdi B, Asgharnejad M, Bauer L, Grieger F, Weintraub D. Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. *Eur J Neurol*. 2016 Oct;23(10):1556-65
295. Volpe D, Giantin MG, Manuela P, Filippetto C, Pelosin E, Abbruzzese G, **Antonini A** Water-based vs. non-water-based physiotherapy for rehabilitation of postural deformities in Parkinson's disease: A randomized controlled pilot study. *Clin Rehabil*. 2016 Aug 10
296. Polli A, Weis L, Biundo R, Thacker M, Turolla A, Koutsikos K, Chaudhuri KR, **Antonini A**. Anatomical and functional correlates of persistent pain in parkinson's disease. *Mov Disord*. 2016 Oct 5. doi: 10.1002/mds.26826.
297. de Cuba CM, Albanese A, **Antonini A**, Cossu G, Deuschl G, Eleopra R, Galati A, Hoffmann CF, Knudsen K, Landi A, Lanotte MM, Marcante A, Mosch A, Pilleri M, Reich MM, Ricchi V, Rinaldo S, Romito LM, Saba FS, Sacristan HE, Schuurman PR, Trezza A, van den Munckhof P, Volkmann J, Zibetti M, Contarino MF. Idiopathic delayed-onset edema surrounding deep brain stimulation leads: Insights from a case series and systematic literature review. *Parkinsonism Relat Disord*. 2016 Sep 6.
298. Fiorenzato E, Weis L, Seppi K, Onofri M, Cortelli P, Zanigni S, Tonon C, Kaufmann H, Shepherd TM, Poewe W, Krismer F, Wenning G, **Antonini A**, Biundo R; Movement Disorders Society MSA (MODIMSA) Neuropsychology and Imaging Study Groups. Brain structural profile of multiple system atrophy patients with cognitive impairment. *J Neural Transm (Vienna)*. 2016 Oct 24.
299. Alzahrani H, **Antonini A**, Venneri A. Apathy in Mild Parkinson's Disease: Neuropsychological and Neuroimaging Evidence. *J Parkinsons Dis*. 2016 Oct 19;6(4):821-832.
300. Nigro S, Arabia G, **Antonini A**, Weis L, Marcante A, Tessitore A, Cirillo M, Tedeschi G, Zanigni S, Calandra-Buonaura G, Tonon C, Pezzoli G, Cilia R, Zappia M, Nicoletti A, Cicero CE, Tinazzi M, Tocco P, Cardobi N, Quattrone A. Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy. *Eur Radiol*. 2016 Oct 19.
301. Volpato C, Schiff S, Facchini S, Silvoni S, Cavinato M, Piccione F, **Antonini A**, Birbaumer N. Dopaminergic medication modulates learning from feedback and error-related negativity in Parkinson's disease: a pilot study *Frontiers in Behavioral Neuroscience* 2016 Nov
302. Fabbri M, Coelho M, Guedes LC, Rosa MM, Abreu D, Gonçalves N, **Antonini A**, Ferreira JJ. Acute response of non-motor symptoms to subthalamic deep brain stimulation in Parkinson's disease. *Parkinsonism Relat Disord*. 2017 Aug;41:113-117.
303. Fiorenzato E, **Antonini A**, Wenning G, Biundo R. Cognitive impairment in multiple system atrophy. *Mov Disord*. 2017 Jul 3.
304. Krüger R, Lingor P, Doskas T, Henselmans JML, Danielsen EH, de Fabregues O, Stefani A, Sensken SC, Parra JC, Onuk K, Yegin A, **Antonini A**. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients. *Adv Ther*. 2017 Jul;34(7):1741-1752.
305. Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Whitwell JL, **Antonini A**, Bhatia KP, Bordelon Y, Corvol JC, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, Höglinger GU; Movement Disorder Society-Endorsed PSP Study Group. Which ante mortem clinical features predict progressive supranuclear palsy pathology? *Mov Disord*. 2017 Jul;32(7):995-1005.
306. Whitwell JL, Höglinger GU, **Antonini A**, Bordelon Y, Boxer AL, Colosimo C, van Eimeren T, Golbe LI, Kassubek J, Kurz C, Litvan I, Pantelyat A, Rabinovici G, Respondek G, Rominger A, Rowe JB, Stamelou M, Josephs KA; Movement Disorder Society-endorsed PSP Study Group. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? *Mov Disord*. 2017 Jul;32(7):955-971. Review.
307. Nigro S, Arabia G, **Antonini A**, Weis L, Marcante A, Tessitore A, Cirillo M, Tedeschi G, Zanigni S, Calandra-Buonaura G, Tonon C, Pezzoli G, Cilia R, Zappia M, Nicoletti A, Cicero CE, Tinazzi M, Tocco P, Cardobi N, Quattrone A. Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy. *Eur Radiol*. 2017 Jun;27(6):2665-2675.
308. Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, **Antonini A**, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I; Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. *Mov Disord*. 2017 Jun;32(6):853-864.
309. Fabbri M, Coelho M, Guedes LC, Chendo I, Sousa C, Rosa MM, Abreu D, Costa N, Godinho C, **Antonini A**, Ferreira JJ. Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test. *Parkinsonism Relat Disord*. 2017 Jun;39:37-43.
310. Sensi M, Cossu G, Mancini F, Pilleri M, Zibetti M, Modugno N, Quatralo R, Tamma F, **Antonini A**; ITALIAN LEVODOPA CARBIDOPA INTESTINAL GEL WORKING GROUP. Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up *Parkinsonism Relat Disord*. 2017 May;38:90-92.

311. **Antonini A**, Barone P, Bonuccelli U, Annoni K, Asgharnejad M, Stanzione P. ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 2017 Apr;88(4):317-324.
312. Lehericy S, Vaillancourt DE, Seppi K, Monchi O, Rektorova I, **Antonini A**, McKeown MJ, Masellis M, Berg D, Rowe JB, Lewis SJG, Williams-Gray CH, Tessitore A, Siebner HR; International Parkinson and Movement Disorder Society (IPMDS)-Neuroimaging Study Group. The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. *Mov Disord*. 2017 Apr;32(4):510-525
313. Caminiti SP, Presotto L, Baroncini D, Garibotto V, Moresco RM, Gianolli L, Volonté MA, **Antonini A**, Perani D. Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease *Neuroimage Clin*. 2017 Mar 27;14:734-740.
314. Martinez-Martin P, Manuel Rojo-Abuin J, Rizos A, Rodriguez-Blazquez C, Trenkwalder C, Perkins L, Sauerbier A, Odin P, **Antonini A**, Chaudhuri KR; KPPS, EUROPAR and the IPMDS Non Motor PD Study Group. Distribution and impact on quality of life of the pain modalities assessed by the King's Parkinson's disease pain scale. *NPJ Parkinsons Dis*. 2017 Mar 15;3:8. doi: 10.1038/s41531-017-0009-1. eCollection 2017.
315. Fiorenzato E, Weis L, Seppi K, Onofri M, Cortelli P, Zanigni S, Tonon C, Kaufmann H, Shepherd TM, Poewe W, Krismer F, Wenning G, **Antonini A**, Biundo R; Movement Disorders Society MSA (MODIMSA) Neuropsychology and Imaging Study Groups. Brain structural profile of multiple system atrophy patients with cognitive impairment. *J Neural Transm (Vienna)*. 2017 Mar;124(3):293-302.
316. Hamel W, Köppen JA, Alesch F, **Antonini A**, Barcia JA, Bergman H, Chabardes S, Contarino MF, Cornu P, Demmel W, Deuschl G, Fasano A, Kühn AA, Limousin P, McIntyre CC, Mehdorn HM, Pilleri M, Pollak P, Rodriguez-Oroz MC, Rumià J, Samuel M, Timmermann L, Valldeoriola F, Vesper J, Visser-Vandewalle V, Volkman J, Lozano AM. Targeting of the Subthalamic Nucleus for Deep Brain Stimulation: A Survey Among Parkinson Disease Specialists. *World Neurosurg*. 2017 Mar;99:41-46.
317. Gandolfi M, Geroin C, **Antonini A**, Smania N, Tinazzi M. Understanding and Treating Pain Syndromes in Parkinson's Disease. *Int Rev Neurobiol*. 2017;134:827-858.
318. Biundo R, Fiorenzato E, **Antonini A**. Nonmotor Symptoms and Natural History of Parkinson's Disease: Evidence From Cognitive Dysfunction and Role of Noninvasive Interventions. *Int Rev Neurobiol*. 2017;133:389-415.
319. Timpka J, Nitu B, Datieva V, Odin P, **Antonini A**. Device-Aided Treatment Strategies in Advanced Parkinson's Disease. *Int Rev Neurobiol*. 2017;132:453-474
320. Fabbri M, Reimão S, Carvalho M, Nunes RG, Abreu D, Guedes LC, Bouça R, Lobo PP, Godinho C, Coelho M, Gonçalves NC, Rosa MM, **Antonini A**, Ferreira JJ. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease. *J Parkinsons Dis*. 2017;7(3):491-501. doi: 10.3233/JPD-171135.
321. de Roos P, Bloem BR, Kelley TA, **Antonini A**, Dodel R, Hagell P, Marras C, Martinez-Martin P, Mehta SH, Odin P, Chaudhuri KR, Weintraub D, Wilson B, Uitti RJ. A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement. *J Parkinsons Dis*. 2017;7(3):533-543.
322. Tsiouris KM, Gatsios D, Rigas G, Miljkovic D, Koroušić Seljak B, Bohanec M, Arredondo MT, **Antonini A**, Konitsiotis S, Koutsouris DD, Fotiadis DI. PD_Manager: an mHealth platform for Parkinson's disease patient management. *Healthc Technol Lett*. 2017 May 23;4(3):102-108. doi: 10.1049/htl.2017.0007
323. Tsiouris KM, Rigas G, Gatsios D, **Antonini A**, Konitsiotis S, Koutsouris DD, Fotiadis DI. Predicting rapid progression of Parkinson's Disease at baseline patients evaluation. *Conf Proc IEEE Eng Med Biol Soc*. 2017 Jul;2017:3898-3901.
324. Fabbri M, Coelho M, Guedes LC, Rosa MM, Abreu D, Gonçalves N, **Antonini A**, Ferreira JJ. Acute response of non-motor symptoms to subthalamic deep brain stimulation in Parkinson's disease. *Parkinsonism Relat Disord*. 2017 Aug;41:113-117. doi: 10.1016/j.parkreldis.2017.05.003.
325. Fabbri M, Guimarães I, Cardoso R, Coelho M, Guedes LC, Rosa MM, Godinho C, Abreu D, Gonçalves N, **Antonini A**, Ferreira JJ. Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson's Disease. *Front Neurol*. 2017 Aug 22;8:432. doi: 10.3389/fneur.2017.00432.
326. **Antonini A**, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtošek Z, Szasz J, Valldeoriola F, Winkler C, Bergmann L, Yegin A, Onuk K, Barch D, Odin P; GLORIA study co-investigators Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. *Parkinsonism Relat Disord*. 2017 Sep 22. pii: S1353-8020(17)30350-4.
327. Biundo R, Weis L, Abbruzzese G, Calandra-Buonaura G, Cortelli P, Jori MC, Lopiano L, Marconi R, Matinella A, Morgante F, Nicoletti A, Tamburini T, Tinazzi M, Zappia M, Vorovenci RJ, **Antonini A**. Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study. *Mov Disord*. 2017 Sep 27. doi: 10.1002/mds.27181
328. Erro R, Brigo F, Tamburin S, Zamboni M, **Antonini A**, Tinazzi M. Nutritional habits, risk, and progression of Parkinson disease. *J Neurol*. 2017 Oct 10. doi: 10.1007/s00415-017-8639-0
329. Bellucci A, **Antonini A**, Pizzi M, Spano P. The End Is the Beginning: Parkinson's Disease in the Light of Brain Imaging. *Front Aging Neurosci*. 2017 Oct 10;9:330. doi: 10.3389/fnagi.2017.00330.
330. Biundo R, Weis L, Fiorenzato E, **Antonini A**. Cognitive Rehabilitation in Parkinson's Disease: Is it Feasible? *Arch Clin Neuropsychol*. 2017 Nov 1;32(7):840-860. doi: 10.1093/arclin/acx092.
331. Tessitore A, Marano P, Modugno N, Pontieri FE, Tambasco N, Canesi M, Latorre A, Lopiano L, Sensi M, Quatratele R, Solla P, Defazio G, Melzi G, Costanzo AM, Gualberti G, di Luzio Papparati U, **Antonini A**. Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study. *J Neurol*. 2018 Mar 7. doi: 10.1007/s00415-018-8816-9.
332. **Antonini A**, Obeso JA. DBS for Parkinson's disease with behavioural disturbances. *Lancet Neurol*. 2018 Mar;17(3):195-197. doi: 10.1016/S1474-4422(18)30044-9.
333. Dafsari HS, Silverdale M, Strack M, Rizos A, Ashkan K, Mählstedt P, Sachse L, Steffen J, Dembek TA, Visser-Vandewalle V, Evans J, Antonini A, Martinez-Martin P, Ray-Chaudhuri K, Timmermann L; EUROPAR and the

- IPMDS Non Motor PD Study Group. Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease. *Mov Disord*. 2018 Mar;33(3):421-430.
334. Bartolomei L, Pastore A, Meligrana L, Sanson E, Bonetto N, Minicuci GM, Marsala SZ, Mesiano T, Bragagnolo L, **Antonini A**. Relevance of sleep quality on caregiver burden in Parkinson's disease. *Neurol Sci*. 2018 Feb 14. doi: 10.1007/s10072-018-3252-2. [Epub ahead of print]
335. Trezza A, Landi A, Pilleri M, **Antonini A**, Giussani C, Sganzerla EP. Peri-electrode edema after bilateral subthalamic deep brain stimulation for Parkinson's disease. *J Neurosurg Sci*. 2018 Feb;62(1):103-105. doi: 10.23736/S0390-5616.16.03421-4.
336. **Antonini A**, Tinazzi M, Abbruzzese G, Berardelli A, Chaudhuri KR, Defazio G, Ferreira J, Martinez-Martin P, Trenkwalder C, Rascol O. Pain in Parkinson disease: facts and uncertainties. *Eur J Neurol*. 2018 Mar 9. doi: 10.1111/ene.13624. [Epub ahead of print]